Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
Research

Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014

Thelma E. TupasiComments to Author , Anna Marie Celina G. Garfin, Ekaterina V. Kurbatova, Joan M. Mangan, Ruth Orillaza-Chi, Leilani C. Naval, Glenn I. Balane, Ramon Basilio, Alexander Golubkov, Evelyn S. Joson, Woo-jin Lew, Vivian Lofranco, Mariquita Mantala, Stuart Pancho, and Jesus N. Sarol
Author affiliations: Tropical Disease Foundation, Inc., Makati City, the Philippines (T.E. Tupasi, L.C. Naval, G.I. Balane, E.S. Joson, J.N. Sarol Jr.); Department of Health, Manila, the Philippines (A.M.C.G. Garfin, R. Basilio); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, J.M. Mangan); Philippine Business for Social Progress–Innovations and Multisectoral Partnership to Achieve Control of Tuberculosis Project, Manila (R. Orillaza-Chi); US Agency for International Development (USAID), Washington, DC, USA (A. Golubkov); World Health Organization Philippines, Manila (W.-j. Lew); The Lung Center of the Philippines, Manila (V. Lofranco, S. Pancho); Technical Assistance to the Countries–USAID-funded activity, Manila (M. Mantala)

Main Article

Table 6

Rating of the severity of medication side effects experienced during treatment for multidrug-resistant TB, the Philippines, 2012–2014*

Side effect
 Total
 Case-patients, mean (SD) score
 Control-patients, mean (SD) score
 Odds ratio (95% CI)†
 p value
Nausea 273 5.05 (3.51) 4.42 (3.18) 1.06 (0.98–1.14) 0.136
Vomiting 273 5.23 (3.72) 4.02 (3.46) 1.10 (1.02–1.18) 0.008
Diarrhea 273 3.34 (3.41) 3.74 (3.18) 0.96 (0.89–1.04) 0.345
Headache 272 4.37 (3.36) 4.20 (3.23) 1.02 (0.94–1.10) 0.689
Sleep disturbances 272 5.23 (3.59) 5.31 (3.26) 0.99 (0.92–1.07) 0.854
Tingling/pain in hands or feet 272 3.58 (3.53) 4.14 (3.56) 0.96 (0.89–1.03) 0.218
Hearing problems 272 4.49 (3.47) 4.13 (3.46) 1.03 (0.96–1.11) 0.417
Dizziness 272 5.48 (3.51) 4.55 (3.14) 1.09 (1.01–1.18) 0.029
Nervousness/anxiety 272 3.26 (3.34) 3.01 (3.16) 1.02 (0.95–1.11) 0.548
Skin problems or rash 272 2.70 (3.26) 2.69 (3.22) 1.00 (0.93–1.08) 0.975
Joint pain 272 5.14 (3.57) 5.49 (3.34) 0.97 (0.90–1.04) 0.427
Vision problems 272 3.10 (3.07) 2.80 (3.05) 1.03 (0.95–1.12) 0.45
Fatigue/extreme tiredness 272 5.18 (3.56) 4.14 (3.25) 1.10 (1.02–1.18) 0.017

*Boldface indicates significance. TB, tuberculosis.
†Odds ratio is per 1 point increase in severity rating score.

Main Article

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external